Pharma heavyweight Pfizer stepping into the prostate cancer ring with AbbVie after inking a $4.2B alliance with Myovant
Myovant $MYOV is ringing out the old year with a big, new commercial partner.
Pfizer $PFE has stepped up with a $4.2 billion deal to partner with the biotech on its newly approved drug relugolix, freighting the deal upfront with $650 million in cash and another $200 million reserved for regulatory decisions as Myovant looks to follow up its win for prostate cancer with 2 other OKs for uterine fibroids and endometriosis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.